DECK 7 Framework for Digital™ Redefines Its B2B Model for 2020 Lead-Gen Goals

DECK 7 | February 04, 2020

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners. The DECK 7 Framework For Digital™ is the outcome of several years of working together with some of the most innovative and successful companies in the world, and is based on the collective learning and shared experiences across thousands of digital marketing campaigns.

Spotlight

Today’s surge of big data coming from multiple sources is raising the stakes that pharmacovigilance has to win, making evidence synthesis a more and more robust approach in the field. In this scenario, many scholars believe that new computational methods derived from data mining will effectively enhance the detection of early warning signals for adverse drug reactions, solving the gauntlets that post-marketing surveillance requires.

Spotlight

Today’s surge of big data coming from multiple sources is raising the stakes that pharmacovigilance has to win, making evidence synthesis a more and more robust approach in the field. In this scenario, many scholars believe that new computational methods derived from data mining will effectively enhance the detection of early warning signals for adverse drug reactions, solving the gauntlets that post-marketing surveillance requires.

Related News

PHARMACY MARKET

Pfizer and BioNTech Announce a Partnership with Biovac to Develop and Distribute COVID-19 Vaccine Doses in Africa

Pfizer | July 22, 2021

Pfizer Inc. and BioNTech SE today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, also known as "Biovac," a South African biopharmaceutical business headquartered in Cape Town, to produce the Pfizer-BioNTech COVID-19 Vaccine for sale inside the African Union. Biovac will manufacture and distribute COVID-19 vaccines as part of Pfizer and BioNTech's worldwide COVID-19 vaccine supply chain and production network, which currently spans three continents and includes more than 20 facilities. Technical transfer, on-site development, and equipment installation operations will begin immediately to enable Biovac's participation in the process. Biovac's Cape Town plant is expected to be integrated into the vaccine supply chain by the end of 2021, according to Pfizer and BioNTech. Biovac will acquire drug substances from European facilities, and final dosage manufacturing will begin in 2022. Annual production will reach 100 million finished dosages at full operating capacity. All dosages will be delivered solely inside the African Union's 55 member states. Quality, compliance, safety track record, technical capability, capacity availability, highly trained workforce, project management abilities, prior working relationship, and commitment to working with flexibility through a fast-paced program are all factors that Pfizer and BioNTech consider when selecting contract manufacturers. Since 2015, Pfizer and Biovac have collaborated on the Prevenar 13 vaccine's sterile formulation, fill, finish, and distribution. Pfizer and BioNTech have delivered more than 1 billion doses of COVID-19 vaccine to more than 100 nations and territories across the globe. The companies are firmly committed to ensuring that all people around the world have equitable and affordable access to COVID-19 vaccines, actively working with global governments and global health partners to provide 2 billion doses to low and middle-income countries in 2021 and 2022 – 1 billion each year. This comprises a non-profit arrangement to provide 500 million doses to the US government, which the government will then give to the African Union and the COVAX 92 Advanced Market Commitment (AMC) nations, as well as a 40 million dose direct supply deal with the COVAX facility. Both BioNTech and Pfizer worked together to create the Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech's unique mRNA technology. In addition to the European Union, BioNTech has emergency use authorizations or equivalent in the United States (jointly with Pfizer), Canada, and other countries in advance of a planned application for full marketing authorizations in these countries. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but it has been approved for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people aged 12 and up. Unless the declaration is ended or the permission withdrawn sooner, the emergency use of this product is only allowed for the duration of the declaration that conditions exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act.

Read More

PHARMACY MARKET

MEDISCA Chooses Creatio to Speed Up Operations and Increase Market Share

MEDISCA | June 18, 2021

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company with 32 years of experience. The company's top priority is to automate processes throughout its sales, service, and marketing divisions and replace at least five disparate systems. "We picked Creatio because of its unified low-code/no-code platform for process management and CRM, which will help us with our business and marketing demands," said Ekaterina Dobrokhotova, Director of Global Marketing. "We can manage the automation of our business processes with Creatio's low-code/no-code tools, giving us more control and flexibility over our operations. It also enables us to put more resources to more complicated, strategic tasks." Creatio aims to assist companies in accelerating by providing solutions to quickly and easily automate business ideas. Creatio provides a modular approach to app development and process automation to help speed up processes even more. The out-of-the-box capacity of Creatio eliminates the need to build core modules for apps from scratch. Instead, its pre-configured modules provide similar basic functionalities required for several apps and can be useful to achieve new solutions more quickly. Solutions Metrix is in charge of the system's implementation. "In the increasingly competitive and rapidly evolving Pharmaceutical compounding market, we are excited to partner with MEDISCA to help them accelerate their growth and achieve strategic business objectives through the power of Creatio's industry-leading low-code/no-code platform," said Thomas James Stewart, Executive Vice-President & Managing Partner. About Solutions Metrix Since 2001, Solutions Metrix has been implementing globally known CRM platforms such as Creatio for the North American market across various industries and businesses of all sizes. CRM consulting services from Solution Metrix focus on accelerating growth and accomplishing strategic business objectives for its partners/clients. Their team of seasoned Business & CRM Consultants will guarantee that every implementation is best practices focused and adapted to your company's specific business processes and needs, using a unique consultative approach & methodology that is ROI & user-adoption driven to assure success. About MEDISCA MEDISCA is the global leader in turnkey solutions for the pharmaceutical compounding industry and associated health care professionals. MEDISCA is committed to being a one-stop-shop for prescribers, pharmacists, and pharmacy technicians involved in personalized medicine by providing high-quality products, cutting-edge technology, industry-leading compounded support, and education through its partnership with LP3 Network. Founded in 1989, the company now has offices in Canada, the United States, and Australia, allowing it to serve the international market better.

Read More

PHARMA TECH

InnovaCare Signs Agreement with MedAvail to Open Three SpotRx Locations in Florida

InnovaCare | November 09, 2021

MedAvail Holdings, Inc. a technology-enabled retail pharmacy company, will be opening an initial three SpotRx locations with InnovaCare Health in Florida in the fourth quarter of 2021. In-clinic SpotRx kiosks and courier home delivery, supported by onsite SpotRx clinic account managers, will be available to patients at three Trinity Medical Center clinics in the Lakeland area. Trinity Medical Center is part of the InnovaCare Health clinical network. SpotRx Pharmacy is the retail pharmacy brand owned and operated by MedAvail in the United States, which deploys and operates the MedAvail MedCenters. “Our physician-led models and innovative technology have placed InnovaCare on the forefront of healthcare transformation for 20 years. We are excited to be continuing this tradition through our partnership with MedAvail and embedding the SpotRx pharmacy in our clinicsWe believe that this collaboration with our skilled clinical teams will result in improved health outcomes for our patients – it is a game-changing technology and the future for pharmacy services.” Connie Garcia, Pharm D., Pharmacy Manager of InnovaCare Health and Trinity Medical Center InnovaCare Health operates more than 30 clinics and is recognized as a leader in transforming care delivery. With the SpotRx embedded pharmacy model, InnovaCare Health patients will receive: Immediate access to prescriptions at the three Trinity Medical Center clinics Free contactless next-day home delivery for all prescriptions and over-the-counter medications Follow up care calls from a local SpotRx pharmacist after receiving the prescription Refill reminder calls on all chronic medications to schedule free delivery or in-clinic pick-up Instant access to SpotRx pharmacists via kiosk or phone “We are honored to support InnovaCare in its efforts to deliver compassionate, high-quality care tailored to each distinct patient population it serves,” said Ed Kilroy, Chief Executive Officer of MedAvail. “Our partnership is another key part of our continued expansion in Florida with our embedded pharmacy solution. We are committed to collaborating with InnovaCare over time to meet its patients’ medication access and adherence needs.” About InnovaCare InnovaCare Health improves the lives of members and physicians through innovative solutions for value-based healthcare. Through an integrated portfolio of health plans, medical service organizations, clinical networks and more, the company manages more than 500,000 lives, including more than 150,000 dual-eligible beneficiaries. InnovaCare’s Medicare Advantage plans have received NCQA accreditation and 4.5-star quality ratings from the Centers for Medicare and Medicaid Services (CMS). About SpotRx SpotRx places control of the pharmacy experience back in the hands of consumers. SpotRx is a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery capability. About MedAvail MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes.

Read More